欧洲STEMI注册研究:再灌注治疗使用与院内结局
该研究为ESC EURObservational Research Programme STEMI注册的前瞻性队列,覆盖29国196中心、11 462例症状发作<24小时的住院STEMI患者。结果显示直接PCI使用率72.2%、溶栓18.8%、无再灌注9.0%,对应院内全因死亡率分别为3.1%、4.4%、14.1%,总体死亡率4.4%。再灌注治疗总体使用率高,但直接PCI使用存在地域差异并与院内死亡率差异相关。
要点
- 直接PCI是欧洲STEMI最常用再灌注策略,总队列使用率72.2%。
- 无再灌注治疗者院内全因死亡率14.1%,明显高于直接PCI的3.1%。
- 直接PCI使用率存在国家间差异(0-100%),并与院内死亡率差异相关。
核心结论
- ESC成员及附属国STEMI再灌注治疗使用率高,直接PCI最常用,总院内死亡率低于5%,但直接PCI使用存在地域差异并与院内死亡率差异相关。
研究设计与样本
- 前瞻性队列(EURObservational Research Programme STEMI注册),纳入29国196中心、症状发作<24小时的住院STEMI患者共11 462例。
主要发现
- 总队列直接PCI使用率72.2%(国家范围0-100%),溶栓18.8%(0-100%),无再灌注治疗9.0%(0-75%)。
- 直接PCI、溶栓、无再灌注对应的院内全因死亡率分别为3.1%、4.4%、14.1%,总体死亡率为4.4%(国家范围2.5-5.9%)。
- 再灌注质量指标达标率:所有STEMI<12小时患者实施再灌注治疗为92.7%(地区范围84.8-97.5%),及时再灌注为54.4%(地区范围37.1-70.1%)。
临床怎么用
- 应优先采用直接PCI作为STEMI再灌注策略,并关注无再灌注治疗患者的高死亡风险。
- 需关注直接PCI使用及及时再灌注达标率的地域差异,针对性改进区域救治体系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). METHODS AND RESULTS: Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset <24 h in 196 centres across 29 countries. A total of 11 462 patients were enrolled, for whom primary percutaneous coronary intervention (PCI) (total cohort frequency: 72.2%, country frequency range 0-100%), fibrinolysis (18.8%; 0-100%), and no reperfusion therapy (9.0%; 0-75%) were performed. Corresponding in-hospital mortality rates from any cause were 3.1%, 4.4%, and 14.1% and overall mortality was 4.4% (country range 2.5-5.9%). Achievement of quality indicators for reperfusion was reported for 92.7% (region range 84.8-97.5%) for the performance of reperfusion therapy of all patients with STEMI <12 h and 54.4% (region range 37.1-70.1%) for timely reperfusion. CONCLUSIONS: The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality.
引用
- Zeymer U, Ludman P, Danchin N, et al. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. Eur Heart J. 2021. PMID: 34389857. doi:10.1093/eurheartj/ehab342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。